Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer

SINGAPORE, Aug. 20, 2018 /PRNewswire/ — Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinica…
( read original story …)


Related Post